Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Adult
Aged
Alleles
Antigen Presentation
Cell Line, Tumor
Epitopes, T-Lymphocyte
/ immunology
Flow Cytometry
HLA-A2 Antigen
/ immunology
Histocompatibility Antigens
/ immunology
Humans
Inflammation
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Mass Spectrometry
Melanoma
/ immunology
Melanoma-Specific Antigens
/ genetics
Mutation
Peptide Library
Exome Sequencing
Immune peptidome
TIL
immunotherapy
mass spectrometry
neoepitopes
tumor
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
08
2019
accepted:
12
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
29
10
2020
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor antigens or mutation-derived neoepitopes. We performed exome sequencing and HLA-A
Identifiants
pubmed: 31921104
doi: 10.3389/fimmu.2019.02766
pmc: PMC6918724
doi:
Substances chimiques
Epitopes, T-Lymphocyte
0
HLA-A2 Antigen
0
Histocompatibility Antigens
0
Melanoma-Specific Antigens
0
Peptide Library
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2766Informations de copyright
Copyright © 2019 Wickström, Lövgren, Volkmar, Reinhold, Duke-Cohan, Hartmann, Rebmann, Mueller, Melief, Maas, Ligtenberg, Hansson, Offringa, Seliger, Poschke, Reinherz and Kiessling.
Références
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Science. 2016 Jun 10;352(6291):1337-41
pubmed: 27198675
J Immunother. 2005 Jan-Feb;28(1):53-62
pubmed: 15614045
Anal Chem. 2010 Nov 1;82(21):9090-9
pubmed: 20932029
Clin Immunol. 2012 May;143(2):99-115
pubmed: 22391152
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
Trends Immunol. 2018 Aug;39(8):596-609
pubmed: 30060805
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344
pubmed: 28601925
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Genes Dev. 2016 Feb 1;30(3):321-36
pubmed: 26833731
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cancer Res. 2013 Jul 1;73(13):3877-87
pubmed: 23633486
J Mol Biol. 2007 Oct 5;372(5):1123-36
pubmed: 17719062
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Front Immunol. 2011 Dec 13;2:75
pubmed: 22566864
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Immunol Rev. 2002 Oct;188:81-96
pubmed: 12445283
Anal Chem. 2003 Oct 15;75(20):5306-16
pubmed: 14710807
J Immunol. 1998 Feb 15;160(4):1750-8
pubmed: 9469433
J Exp Med. 2007 Sep 3;204(9):2187-98
pubmed: 17709425
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16009-14
pubmed: 24043806
J Immunol Methods. 2003 Oct 1;281(1-2):65-78
pubmed: 14580882
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8204-E8213
pubmed: 28811364
Clin Cancer Res. 2011 May 1;17(9):2668-78
pubmed: 21248298
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Cancer Immunol Res. 2014 Jun;2(6):522-9
pubmed: 24894089
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
J Immunol. 2004 May 15;172(10):6057-64
pubmed: 15128789
Nat Med. 2013 Jun;19(6):747-52
pubmed: 23644516
Med Oncol. 2004;21(1):49-52
pubmed: 15034213
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Front Immunol. 2017 Nov 30;8:1702
pubmed: 29250075
J Exp Med. 2014 Oct 20;211(11):2231-48
pubmed: 25245761
Cancer Immunol Immunother. 2014 Oct;63(10):1061-71
pubmed: 24993563
Trends Immunol. 2011 Nov;32(11):548-58
pubmed: 21962745
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Semin Oncol. 2015 Aug;42(4):626-39
pubmed: 26320066
Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2151-6
pubmed: 25646416
Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62
pubmed: 14706621